[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.157.73. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
April 7, 2004

Predictors of Clinical Response of Non–Small Cell Cancer to Gefitinib

Author Affiliations
 

Letters Section Editor: Stephen J. Lurie, MD, PhD, Senior Editor.

JAMA. 2004;291(13):1563. doi:10.1001/jama.291.13.1563-a

To the Editor: Dr Kris and colleagues1 reported that gefitinib improved both symptoms and radiological responses in patients with non–small cell lung cancer who had previously undergone standard chemotherapy.

Although the authors reported that female sex and adenocarcinoma histology were predictive of favorable response to gefitinib, they apparently did not assess response to previous chemotherapy. It would be of interest to know if this is predictive of a positive outcome. For instance, Shepherd et al2 reported that of 6 patients who responded to docetaxel, 3 had had a positive response to standard chemotherapy treatment and the other 3 had achieved stable disease; no patient who responded to docetaxel had progressed while receiving platinum-based chemotherapy.2

First Page Preview View Large
First page PDF preview
First page PDF preview
×